FDA Approves Inavolisib Combo for PIK3CA-Mutated, HR+ Breast Cancer

References

1. FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer. 2024 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive
2. Juric D. Kalinsky K. Turner N.C. Jhaveri K.L. Schmid P. Loi S. Saura C. Im S-A. Sunpaweravong P. Li H. Musolino A. Zhang Q. Nowecki Z. Leung R.C-Y. Thanopoulou E. Shankar N. Lei G. Devine J. Stout T.J. Loibl S. First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA -mutated, hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. J. Clin. Oncol. 2024 42 16_suppl Suppl. 1003 1003 10.1200/JCO.2024.42.16_suppl.1003
   [Google Scholar]
3. A study evaluating the efficacy and safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, her2-negative, locally advanced or metastatic breast cancer. 2024 NC Patent T04191499
4. Hanan E.J. Braun M.G. Heald R.A. MacLeod C. Chan C. Clausen S. Edgar K.A. Eigenbrot C. Elliott R. Endres N. Friedman L.S. Gogol E. Gu X.H. Thibodeau R.H. Jackson P.S. Kiefer J.R. Knight J.D. Nannini M. Narukulla R. Pace A. Pang J. Purkey H.E. Salphati L. Sampath D. Schmidt S. Sideris S. Song K. Sujatha-Bhaskar S. Ultsch M. Wallweber H. Xin J. Yeap S. Young A. Zhong Y. Staben S.T. Discovery of GDC-0077 (Inavolisib), a highly selective inhibitor and degrader of mutant PI3Kα. J. Med. Chem. 2022 65 24 16589 16621 10.1021/acs.jmedchem.2c01422 36455032
   [Google Scholar]
5. Edgar K. Hong R. Song K. Schmidt S. Hafner M. Arrazate A. Williams E. Cruz C.D.L. Oeh J. Sampath D. Staben S. Friedman L. Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. Cancer Res 2020 80 4 P3-11-23 -P13-11-23.
   [Google Scholar]
6. Hong R. Edgar K. Song K. Steven S. Young A. Hamilton P. Arrazate A. De La Cruz C. Chan C. Pang J. Salphati L. Belvin M. Nannini M. Staben S. Friedman L. Sampath D. Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies Cancer Res 2018 78 4 10.1158/1538‑7445.SABCS17‑PD4‑14
   [Google Scholar]
7. Jhaveri K.L. Accordino M.K. Bedard P.L. Cervantes A. Gambardella V. Hamilton E. Italiano A. Kalinsky K. Krop I.E. Oliveira M. Schmid P. Saura C. Turner N.C. Varga A. Cheeti S. Hilz S. Hutchinson K.E. Jin Y. Royer-Joo S. Peters U. Shankar N. Schutzman J.L. Juric D. Phase I/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA -mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. J. Clin. Oncol. 2024 42 33 3947 3956 10.1200/JCO.24.00110 39236276
   [Google Scholar]
8. André F. Ciruelos E. Rubovszky G. Campone M. Loibl S. Rugo H.S. Iwata H. Conte P. Mayer I.A. Kaufman B. Yamashita T. Lu Y.S. Inoue K. Takahashi M. Pápai Z. Longin A.S. Mills D. Wilke C. Hirawat S. Juric D. Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer. N. Engl. J. Med. 2019 380 20 1929 1940 10.1056/NEJMoa1813904 31091374
   [Google Scholar]
9. Hotaki L.T. Shrestha A. Bennett M.P. Valdes I.L. Lee S.H. Wang Y. Spillman D. MacAulay T. Hunt M. Gervais J. Mafi M. Panetta V. Looi Y.H. Shum M. Atiek E. Meincke R. Rohr U.P. Ainbinder D. Boehm-Cagan A. Luxenburg O. Cerqueira M.R. Mouawad L.S. Thees M.F.R.S. Prasad K. de Claro R.A. Comparative expedited regulatory programs of U.S Food & Drug administration and project orbis partners. Ther. Innov. Regul. Sci. 2023 57 4 875 885 10.1007/s43441‑023‑00522‑4 37072651
   [Google Scholar]